A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Exclusion Criteria

• •Deceased donor kidney graft qualified as expanded criteria donor or donor after cardiac death.
• •Positive T or B cell crossmatch, or positive virtual crossmatch per local practice at screening.
• •Participants receiving a kidney graft from HLA-identical living-related donors, or have current or previous solid organ, cell, or multi-organ transplantation, or paired kidney transplantation.
• •Participants whose primary causes of ESKD are idiopathic FSGS, C3 glomerulopathy, lupus nephritis, or thrombotic microangiopathy
• •Evidence of active or latent TB, HIV, HBV or HCV infection.
• •Participants who have known genetically predisposed thrombophilia, have history of thromboembolic events, or who need long-term anti-coagulation therapy.
• •Participants who have severe medical co-morbidities, active infection, or severely limited life expectancy due to underlying medical conditions that are generally precluded from kidney transplant.
• •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.